USD
EUR
GBP
CAD
AUD
CHF
HKD
JPY
RUB
BRL
CLP
NOK
DKK
SEK
KRW
ILS
MXN
CNY
SAR
SGD
NZD
ARS
INR
COP
AED
Home
Products
Peptides
Nootropics
Steriods
Sarms
Custom synthesis
Others
About Us
About Us
Sitemap
FAQ
Blog
News
Download
Contact Us
0
Home
Products
Peptides
Nootropics
Steriods
Sarms
Custom synthesis
Others
About Us
About Us
Sitemap
FAQ
Blog
News
Download
Contact Us
Home
>
News
News
Short-term Clinical Outcomes of Upadacitinib in Patients with Rheumatoid Arthritis
Jun 16, 2023
06-16
2023
Chemical Name: Upadacitinib
CAS No.: 1310726-60-3
Molecular Formula: C17H19F3N6O
Formula Weight: 380.37
Linsitinib, a new drug in development
Jun 13, 2023
06-13
2023
Chemical Name: Linsitinib
Molecular Formula: C26H23N5O
Formula Weight: 421.49
CAS No.: 867160-71-2
New major depression trigger mechanism discovered, and glycine plays a crucial part!
Jun 12, 2023
06-12
2023
New major depression trigger mechanism discovered, and glycine plays a crucial part!
A recent research discovered that the ubiquitous amino acid glycine can communicate "braking" signals to the brain that may have an impact on certain people's significant depression, anxiety, and other mood disorders. The study's findings, titled "Orphan receptor GPR158 serves as a metabotropic glycine receptor: mGlyR," were published onlinein Science on March 30.
sarms4muscle-oxiracetam,piracetam powder products video
Jun 02, 2023
06-02
2023
How Pramiracetam Capsules Can Boost Productivity and Mental Clarity
May 29, 2023
05-29
2023
Otsuka Pharmaceutical's (Otsuka) ponatinib tablet (ponatinib) marketing application was accepted by the State Drug Administration.
May 12, 2023
05-12
2023
Name: ponatinib
CAS: 943319-70-8
Voxelotor, a drug for sickle cell disease
May 10, 2023
05-10
2023
Voxelotor, a drug for sickle cell disease
Name: Voxelotor
CAS: 1446321-46-5
Originating company: Global Blood Therapeutics
Indication: Sickle cell disease
NASH Research Update│Resmetirom Receives Breakthrough Therapy Designation from FDA
May 10, 2023
05-10
2023
NASH Research Update│Resmetirom Receives Breakthrough Therapy Designation from FDA
NASH treatment drug hits high note: Resmetirom Phase III progress excellent
May 09, 2023
05-09
2023
NASH treatment drug hits high note: Resmetirom Phase III progress excellent
AstraZeneca's 'semitinib' approved in China
May 09, 2023
05-09
2023
AstraZeneca's 'semitinib' approved in China,Company News
semitinib (AstraZeneca/Mercedon), binitinib (Pfizer/Pierre Fabre/Ono Pharmaceutical), cobimetinib (Roche/Exelixis), and trametinib (Japan Tobacco/Novartis)
1
...
3
4
5
6
7
8
9
page:
Go
